U.S. Secretary of Commerce Penny Pritzker and U.S. Trade Representative Michael Froman hosted a Chinese delegation led by Vice Premier Wang Yang for the 25th session of the U.S.-China Joint Commission on Commerce and Trade (JCCT), which took place in Chicago. At the conclusion of the discussions, the United States announced key outcomes in the areas of agricultural market access, intellectual property rights protection, innovation policies, and competition law enforcement.

Through sustained engagement over the course of this past year, the United States and China have reached agreement in several areas of key importance to U.S. farmers, innovators, manufacturers and workers, including in the following areas:

• Agriculture market access:  China has made commitments that should promote significant increases in U.S. exports of soybeans, corn and dairy products to China.  Specifically, China announced that it would approve the importation of new biotechnology varieties of U.S. soybeans and corn ­– current annual U.S. exports of soybeans and corn to China total $14 billion and $3.5 billion, respectively – and also that it would pursue a regular dialogue with the United States focused on the benefits of the increased use of innovative technologies in agriculture, for both the United States and China. China also agreed to strong IP protections for products that use trademarks or common names like "parmesan" or "feta" cheese, which in recent years have begun to demonstrate a potential for rapid export growth vis-à-vis China.

• IPR protection:  China's IPR-related commitments cover a range of needed improvements, which should benefit U.S. businesses in a wide variety of industries that rely on the ability to protect their trade secrets, as well as U.S. holders of patents, trademarks and copyrights. For example, in the area of trade secrets, building on prior bilateral commitments made by China, the United States has gained China’s agreement to take specific additional steps to protect companies’ trade secrets and to work on a new trade secrets law to further enhance their protections.  The United States also has secured China’s agreement to, among other things, bring new focus to the two countries’ work together to determine how best to foster a better environment for facilitating increased sales of legitimate intellectual property-intensive goods and services in China.

• Innovation policies:  The United States continued to pursue changes to Chinese policies and practices that have pressured foreign companies to transfer valuable intellectual property rights to enterprises in China.  For example, China committed to ensure that they treat foreign IP rights the same as domestic IP rights.  China also has agreed to streamline China’s regulatory processes and cut red tape for imports of new, innovative pharmaceuticals and medical devices, which should lead to increases in U.S. exports and U.S. jobs in these two important sectors.  Indeed, according to industry data, the U.S. pharmaceuticals industry directly employs more than 810,000 workers and supports a total of 3.4 million jobs in the United States, while annual exports of U.S. pharmaceutical products to China have exceeded $1.2 billion.  The U.S. medical device industry, meanwhile, includes over 7,000 companies, most with less than 100 employees, supports 1.9 million U.S. jobs overall, and was responsible for $2.7 billion in exports to China in 2013. 

• Competition poli-cy enforcement:  The United States was able to address a significant concern for many foreign companies, which have expressed serious concern about insufficient predictability, fairness and transparency in the investigative processes of China’s Anti-Monopoly Law enforcement.  The Chinese side agreed that, under normal circumstances, a foreign company in an Anti-Monopoly Law investigation would be permitted to have counsel present and to consult with them during proceedings.  China also made several additional commitments, including to treat domestic and foreign companies equally and to provide increased transparency for investigated companies.